C
Claes Ginman
Researcher at Uppsala University
Publications - 18
Citations - 900
Claes Ginman is an academic researcher from Uppsala University. The author has contributed to research in topics: Docetaxel & Prostate cancer. The author has an hindex of 9, co-authored 17 publications receiving 607 citations.
Papers
More filters
Journal ArticleDOI
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
Anders Widmark,Adalsteinn Gunnlaugsson,Lars Beckman,Camilla Thellenberg-Karlsson,Morten Høyer,Magnus Lagerlund,Jon Kindblom,Claes Ginman,Bengt Johansson,Kirsten Björnlinger,Mihajl Seke,Måns Agrup,Per Fransson,Björn Tavelin,David Norman,Björn Zackrisson,Harald Anderson,Elisabeth Kjellén,Lars Franzén,Per Nilsson +19 more
TL;DR: There was weak evidence of an increased frequency of acute physician-reported RTOG grade 2 or worse urinary toxicity in the ultra-hypofractionation group at end of radiotherapy, consistent with the physician-evaluated toxicity.
Journal ArticleDOI
2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial
Pirkko-Liisa Kellokumpu-Lehtinen,Ulrika Harmenberg,Timo Joensuu,Ray McDermott,Petteri Hervonen,Claes Ginman,Marjaana Luukkaa,Paul Nyandoto,Akseli Hemminki,Sten Nilsson,John McCaffrey,Raija Asola,Taina Turpeenniemi-Hujanen,Fredrik Laestadius,Tiina Tasmuth,Katinka Sandberg,Maccon M. Keane,Ilari Lehtinen,Tiina Luukkaala,Heikki Joensuu +19 more
TL;DR: Administration of docetaxel every 2 weeks seems to be well tolerated in patients with castration-resistant advanced prostate cancer and could be a useful option when 3-weekly single-dose administration is unlikely to be tolerated.
Journal ArticleDOI
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial
Per Fransson,Per Nilsson,Adalsteinn Gunnlaugsson,Lars Beckman,Björn Tavelin,David Norman,Camilla Thellenberg-Karlsson,Morten Høyer,Magnus Lagerlund,Jon Kindblom,Claes Ginman,Bengt Johansson,Kirsten Björnlinger,Mihajl Seke,Måns Agrup,Björn Zackrisson,Elisabeth Kjellén,Lars Franzén,Anders Widmark +18 more
TL;DR: The HYPO-RT-PC trial as mentioned in this paper compared conventional fractionation and ultra-hypofractionation up to 6 years after treatment in patients with localised prostate cancer, and the results showed that UHF was non-inferior to traditional fractionation regarding 5-year failure-free survival and toxicity.
Journal ArticleDOI
Extreme Hypofractionation versus Conventionally Fractionated Radiotherapy for Intermediate Risk Prostate Cancer : Early Toxicity Results from the Scandinavian Randomized Phase III Trial "HYPO-RT-PC"
Anders Widmark,Adalsteinn Gunnlaugsson,Lars Beckman,Camilla Thellenberg-Karlsson,Morten Høyer,Magnus Lagerlund,Per Fransson,Jon Kindblom,Claes Ginman,Bengt Johansson,Mihalj Seke,Kirsten Björnlinger,Elisabeth Kjellén,Lars Franzén,Per Nilsson +14 more
TL;DR: Extreme Hypofractionation versus Conventionally Fractionated Radiotherapy for Intermediate Risk Prostate Cancer and early Toxicity Results from the Scandinavian Randomized Phase III Trial "HYPO-RT-PC" are presented.
Journal ArticleDOI
Palliation of Bone Pain in Prostate Cancer Using Chemotherapy and Strontium-89. A Randomized Phase II Study
Sten Nilsson,Peter Strang,Claes Ginman,Rolf Zimmermann,Maliha Edgren,Britta Nordström,Marianne Ryberg,Karl-Mikael Kälkner,Jan-Erik Westlin +8 more
TL;DR: The effect of FEM on pain is surprising as chemotherapy has generally only limited effect on tumor growth in bone metastases due to prostate cancer.